Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. It is induced by plasma cells via angiogenic factors with the transition from monoclonal gammopathy of undetermined significance (MGUS) to MM, and probably with loss of angiostatic activity on the part of MGUS. The pathophysiology of MM-induced angiogenesis is complex and involves both direct production of angiogenic cytokines by plasma cells and their induction within the microenvironment. The latter are secreted by stromal cells, endothelial cells (EC) and osteoclasts, and promote plasma cell growth, survival and migration, as well as paracrine cytokine secretion and angiogenesis in the bone marrow milieu. Angiogenesis is also supported by inflammatory cells following their recruitment and activation by plasma cells. Finally, circulating EC and endothelial precursor cells (EPC) contribute to the neovascularization, and the presence of EPC suggests that vasculogenesis (new vessel formation from EPC) may also contribute to the full MM vascular tree.
Introduction
Angiogenesis is uncontrolled and unlimited in time, and essential for tumor growth, invasion and metastasis during the transition from the avascular to the vascular phase. The growth of solid tumors is certainly angiogenesis-dependent, whereas the role of angiogenesis in the growth and survival of hematological malignancies has only recently rendered evident.
Here we present an overview of the literature focusing on the relationship between angiogenesis and disease progression in multiple myeloma (MM), the regulatory angiogenic cytokines, the angiogenic switch occurring with progression, the invasive ability of tumor plasma cells, the importance of MM endothelial cells (EC), endothelial precursor cells (EPC) and microenvironment in MM neovascularization, the prognostic value of angiogenesis in MM and the recent advances in the antiangiogenic treatment of this disease.
Tumor progression in MM goes hand in hand with a bone marrow vascular phase
The microvessel density (MVD) of bone marrow biopsies from patients with active and nonactive MM and with monoclonal gammopathies of undetermined significance (MGUS) has been investigated with immunoperoxidase and an antibody to the endothelial cell marker factor VIII-related antigen. 1 The labeling index (LI%) of plasma cells aspirated from the biopsy site was also assessed. The microvessel area in active MM patients was significantly higher than in nonactive MM and MGUS patients. The area varied in function of the LI% and both parameters were closely correlated, whereas it was not correlated with plasmocytosis. 1 Other morphological and functional studies by us 1, 2 are summarized in Table 1 .
Overall, these findings suggest that, like solid tumor cells, highly proliferating plasma cells possess an angiogenic capability via the release of angiogenic cytokines (see below). As the progression from in situ to invasive and metastatic solid tumors is accompanied and enhanced by the switch from the avascular to the vascular phase, they suggest that active MM is the 'vascular phase' of plasma cell tumors, wheras nonactive MM and MGUS are their 'avascular phase'. Bone marrow angiogenesis may therefore favor progression from MGUS or nonactive MM to active MM. Studies by Rajkumar et al. 3, 4 Dominici et al., 5 Laroche et al. 6 and Moehler et al. 7 have confirmed substantial bone marrow neovascularization in MM.
Angiogenic cytokines and MM progression
ELISA on plasma cell lysates showed that fibroblast growth factor-2 (FGF-2) levels were significantly higher in active MM patients compared with nonactive MM and MGUS patients. 2 A neutralizing anti-FGF-2 antibody inhibited the angiogenic activity exerted on cultured human umbilical vein EC (HUVEC) by the plasma cell conditioned medium (CM) and inhibition was also obtained on angiogenesis induced in the chick embryo chorioallantoic membrane (CAM) assay by the CM. 2 These results agree with those obtained in patients with B-cell chronic lymphocytic leukemia, showing that overexpression of FGF-2 parallels progression. 8 On the contrary, Gupta et al. 9 did not detect FGF-2 in MM cell lines and patients' plasma cells, and Colla et al. 10 rarely found its direct production by MM cells, suggesting that it is not a major angiogenic factor produced by MM cells. Bone marrow stromal cells (BMSC) from MM patients and normal donors secreted FGF-2, but this decreased in cocultures with plasma cells.
Human leukemia, lymphoma and MM cell lines were found to express the vascular endothelial growth factor (VEGF) mRNA, and secrete the protein into the extracellular environment.
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Some MM cell lines also expressed the VEGF receptor-1 (VEGFR-1), and an autocrine pathway for tumor growth was demonstrated ( Figure 1 ). 12 Plasma cells in the bone marrow of patients with MM expressed VEGF, whereas both VEGFR-1 and VEGFR-2 were markedly elevated in the BMSC, suggesting that a paracrine growth pathway mediated by VEGF-activated stromal cells, secretion of interleukin-6 (IL-6) on their part, and subsequent activation of plasma cells may occur (Figure 1) . In active MM, we found secretion of the VEGF-A isoform by plasma cells, overexpression of VEGFR-2 by bone marrow microvessels and isolated EC and of VEGFR-1 by the other stromal cells, secretion of VEGF-C and VEGF-D by stromal cells, and expression of their cognate receptor VEGFR-3 by plasma cells, which suggests another paracrine loop of angiogenesis and tumor growth in MM (Figure 1) . 13 Parallel studies by Kumar et al. 14 found secretion of VEGF by several MM cell lines and fresh patients' bone marrow plasma cells, as well as cell expression of VEGFR-1 and VEGFR-2, which suggests multiple VEGF-mediated autocrine pathways of tumor growth and paracrine stimulation of angiogenesis ( Figure 1 ). VEGF-A is also released by fetal BMSC and interacts with VEGFR-1 expressed on MM plasma cells. 15 This provides further evidence of paracrine tumor proliferation and migration. 16 Murine MM cells were found to be a rich source of VEGF through which they induced angiogenesis in an in vitro model. 17 Hepatocyte growth factor/scatter factor (HGF/SF) is yet another angiogenic factor identified in the CM of both human MM cell lines 18 and freshly isolated plasma cells. 19 Serum levels of this factor were high in 43% of patients at diagnosis, fell to normal levels if a response to induction therapy was achieved and rose again upon relapse, indicating that it is a typical plasma cell product. 20 FGF-2, VEGF and HGF/SF were all found to be more expressed in the bone marrow than peripheral blood plasma, indicating that the bone marrow is their prime source. 20 Still other factors may be responsible for bone marrow angiogenesis in MM: the plasma cell secretion products, such as transforming growth factor-b (TGF-b) and IL-1b; IL-6 and IL-8; 21 granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and TNF-a, 22 secreted by bone marrow microenvironment cells recruited and activated by plasma cells. IL-6, IL-8, GM-CSF and IL-1b, indeed, are mostly secreted in the MM active phase 22 where the vascular phase was found. Since human MM cell lines produce angiopoietin-1 (Ang1) that upregulates the Tie2 cognate receptor in bone marrow EC, involvement of the Ang1-Tie2 loop in MM neovascularization has also been postulated. 23 MM patients' bone marrow EC (MMEC) express and secrete higher amounts of the CXC chemokines IL-8, interferoninducible T-cell-a chemoattractant (I-TAC), stromal cell derived factor 1a (SDF-1a), and monocyte chemotactic protein-1 (MCP-1) than healthy HUVEC. 24 Paired plasma cells and several MM cell lines expressed cognate receptors of each chemokine to a variable extent. When cells were exposed to chemokines, IL-8 and SDF-1a stimulated their proliferation and all chemokines their chemotaxis. It is suggested that angiogenesis also favors MM progression through the release of CXC chemokines.
Munshi et al. 25 compared the gene expression of patients' bone marrow plasma cells with healthy plasma cells, and found increased expression of angiogenesis-related IL-8 and Ang1 transcripts in patients' plasma cells, whereas IL-6 and VEGF were not varied.
Recently, the direct production of osteopontin, the expression and activity of its major regulating gene Runx2/Cbfa1 in MM cells, and the potential role of osteopontin in plasma cellinduced bone marrow angiogenesis have been elucidated.
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The angiogenic switch
The cause of the induction of the vascular phase on the transition from MGUS to MM or from nonactive to active MM is still unknown. Equal amounts of plasma cell lysates from active MM patients and from nonactive MM or MGUS patients gave significantly higher levels of FGF-2 in the former. 2 We hypothesized that the angiogenic switch was owing to an increase in FGF-2 production and secretion by plasma cells, probably caused by expression of oncogenes (c-myc, c-fos, c-jun, ets-1) coding for angiogenic factors, and activated as a consequence of immunoglobulin (Ig) translocations and genetic instability of plasma cells 28 ( Figure 2 ). Accordingly, by using a murine model for MM, Asosingh et al. 29 showed that the switch is preceded by the expression of mRNA for VEGF and secretion of protein by plasma cells. Furthermore, they demonstrated that the angiogenic switch was preceded by a shift from CD45 positive to CD45 negative plasma cells, and increased production of VEGF by the CD45 negative cells. Other studies, however, showed that the expression levels of VEGF, FGF-2, and their receptors were similar among plasma cells from MGUS, smoldering MM and newly-diagnosed MM, suggesting that increasing angiogenesis from MGUS to MM is, at least in part, explained by increased tumor burden rather than increased expression of VEGF/FGF-2 by single plasma cells. 30 Another possibility is that the inhibition of angiogenesis in MGUS is lost with progression, hence that the switch from MGUS to MM may involve a loss of an antiangiogenic activity 30 ( Figure 2 ).
Invasive ability of plasma cells
Enriched bone marrow plasma cells expressed matrix metalloproteinase-2 (MMP-2), whereas the expression of MMP-9 was less intense and inconstant, and secreted both enzymes into the CM. 2,31 Barillé et al. 32 have shown production of MMP-9 by several MM cell lines and freshly isolated bone marrow plasma cells and demonstrated that BMSC constitutively produce MMP-1 and MMP-2. Furthermore, IL-1b and TNF-a, produced by MM plasma cells and BMSC, respectively, 20 enhance MMP-1 production. Given the ability of MMP-1, MMP-2 and MMP-9 to degrade collagens and fibronectin, the data suggest that plasma cells of active MM patients are especially capable of invading both the stroma and the subendothelial basement membrane. In addition, ECM degradation brings about the release of its stored angiogenic factors. Taken as a whole, therefore, the data suggest that major proteolytic activity and angiogenesis occur together close to plasma cells and that the conditions for their intra-and extramedullary dissemination are established. 28 Fresh bone marrow plasma cells from MM patients are able to interact with immobilized vitronectin and fibronectin through avb3 integrin. 33 This interaction allows their prompt adhesion to the substratum and rapidly induces their recruitment of the b3 integrin subunit together with the cytoskeletal components vinculin and paxillin and results in an increase in MMP-2, MMP-9 and uPA secretion. Podar et al. 34 have shown that VEGF stimulates migration of an MM cell line and cell attachment to fibronectin via a1 integrin and protein kinase C activation. Data imply that plasma cell adhesion to the fibronectin and vitronectin and subsequent stimulation of cell proliferation, migration and protease secretion are enhanced by several integrin complexes. The enhanced invasive ability of plasma cells along with their increased angiogenic capacity and induction of the vascular phase in active MM may explain its frequent intramedullary and extramedullary dissemination. 28 Results also suggest that tyrosine-kinase inhibitors have therapeutic potential in MM. 11 Finally, MM plasma cells in a murine model were found to adhere more strongly to bone marrow, spleen and liver EC than lung, heart, intestine, kidney and testis EC 35 via CD44 molecule.
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MMEC: are they tumoral?
Long-term cultured EC from the bone marrow of patients with MM were compared with EC from patients with MGUS and HUVEC as their normal quiescent counterpart. 37 MMEC showed enhanced morphological activation compared to HUVEC and expressed 5-70 times higher levels of several vascular markers (Tie2, VEGFR-2, FGFR-2, CD105-endoglin, and vascular endothelial [VE]-cadherin) than HUVEC. They produced 4-40 times more FGF-2 and VEGF, and 3-5 times more MMP-2 and MMP-9 than HUVEC. They gave a growth advantage over HUVEC because they quickly formed a closely knit capillary plexus with multicentric junctions and sprouts, whereas the plexus of the other EC was loose with few junctions and sprouts. MMEC induced an intense angiogenic response in the CAM. On Figure 2 A hypothesis on the angiogenic switch in multiple myeloma. Primary and secondary translocations in MGUS and smoldering myeloma respectively, together with chromosomal instability, lead to activation of oncogenes and inactivation of tumor-suppressor genes, which induce genes coding for angiogenic cytokines. Tissue hypoxia with consequent VEGF secretion, as well as activation of bone marrow stromal cells (BMSC) are additional events: the angiogenic switch occurs and parallels transition to multiple myeloma.
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a cDNA microarray, MMEC displayed upregulation of angiogenic genes (VEGF and FGF isoforms, HGF/SF, Tie2, TGF-b, Gro-a chemokine, fibronectin-1, HIF-1a, ETS-1, ID3, and osteopontin) compared to HUVEC. MMEC alone displayed a VEGF-dependent autocrine growth loop, 38 owing to high VEGF-A and VEGFR-2 expression (Figure 2) , constitutive autophosphorylation in both VEGFR-2 and the associated kinase ERK-2, and inhibition of proliferation, capillarogenesis and phosphorylation by neutralizing anti-VEGF-A and anti-VEGFR-2 antibodies. Overall findings seem to point to a tumoral phenotype of MMEC: either plasma cells and MMEC derive from a common tumor precursor cell, or MMEC are hybrids of plasma cells with existing EC. These hypotheses have been recently demonstrated in EC of B-cell lymphomas. 39 Therapeutic doses of thalidomide markedly downregulate key angiogenic genes in MMEC and Kaposi's sarcoma (KS) cell line, but upregulate them or are ineffective in nonactive MMEC, bone marrow EC from diffuse large B-cell lymphoma and in HUVEC. 40 Secretion of VEGF, FGF-2 and HGF/SF also diminishes according to the dose in culture CM of active MMEC and KS, whereas it does not change in the other CM. Data confirm an overlapping behavior (as to the thalidomide treatment) of MMEC and a tumoral EC such as KS cells, and suggest that inhibition by thalidomide is probably confined to the genes of active MMEC and KS.
The role of EPC
Circulating EPC have been detected after vascular injury and during tumor growth. 41 The molecular and cellular mechanisms underlying EPC recruitment and differentiation are not understood yet, and remain as one of the central issues in stem cell biology. In MM, circulating EPC have not been characterized and their role in disease pathogenesis and progression are unknown. Zhang et al. 42 tested the hypothesis that their level and function correlate with disease activity. They demonstrated sixfold higher percentages of circulating EC and EPC in MM patients than healthy subjects. 42 These percentages fluctuated concordantly with the serum M-component and b2-microglobulin (markers of the MM cell mass and activity) and fell in response to effective treatment with thalidomide and CC-5013. These data indicate that circulating EPC may be a marker of MM severity and response to therapy, and be involved in vasculogenesis (neovessel formation from EPC), thus contributing along with angiogenesis to the formation of the full MM vascular tree.
The role of microenvironment in MM angiogenesis
The MM microenvironment is characterized by the presence of plasma cells, ECM proteins, hematopoietic stem cells and BMSC, including fibroblasts, osteoblasts, osteoclasts, chondrocytes, EC, EPC, T lymphocytes, macrophages and mast cells, which are intimately involved in all biological stages of intramedullary growth. 43 Interactions between these components determine the proliferation, migration and survival of plasma cells, as well as acquisition of drug resistance and formation of bone disease. 42 Binding of plasma cells to BMSC upregulates transcription and secretion of IL-6 within the latter and, on its part, IL-6 stimulates VEGF secretion by IL-6R-expressing plasma cells. 44 IL-6 acts as a stimulator of the plasma cell VEGF-VEGFR-1 autocrine loop for growth and chemotaxis, 11 while VEGF secreted by plasma cells increases IL-6 production by BMSC via VEGFR-2, thus forming a paracrine loop for growth ( Figure 1) . 44 Moreover, a specific activity of CD40 has been demonstrated in inducing secretion of VEGF by plasma cells and their migration, suggesting its critical role in regulating MM homing and angiogenesis. 45 It may well be that these plasma cell-BMSC interactions along with the secretion of angiogenic cytokines by plasma cells recruit and activate BMSC to secrete their own angiogenic cytokines during the angiogenic switch 28 ( Figure 2) .
Asosingh et al. 46 underlined the important role of hypoxic bone marrow microenvironment in MM tumor progression and angiogenesis (Figure 2) . By using the 5T2MM mouse model, they demonstrated that bone marrow hypoxia is advantageous for the tumor-initiating MM cells. Together with the hypoxia in myeloma-infiltrated bone marrow and consequent secretion of VEGF by plasma cells, the study also indicates that myelomaassociated angiogenesis is functional and permissive for the expansion of MM cells.
Synergism of bone marrow stromal cells in inducing the angiogenic response
Most studies on tumor changeover have focused on events that occur around transformed cells. The specific organ microenvironment determines the extent of cancer cell proliferation, angiogenesis, invasion and survival. 47 BMSC (which represent inflammatory cells in the MM bone marrow) may act synergistically with tumor cells by secreting the same or other angiogenic factors. Mast cells play a pivotal role in this synergism, because they are a rich source of pre-formed and newly synthesized angiogenic cytokines and growth factors, such as TNF-a, IL-8, FGF-2 and VEGF, [48] [49] [50] and proteases, such as tryptase 51 and chymase, 52 which are contained in their secretory granules. In fact, bone marrow angiogenesis, evaluated as microvessel area, and mast cell counts are highly correlated in patients with nonactive and active MM and in those with MGUS, and both parameters increase simultaneously in active MM. 53 These data agree with those showing coexistence of neovessels and inflammatory cells in the human MM SCID mouse model. 54 Noteworthy is the fact that mast cells may promote the growth of plasma cell tumors through secretion of Ang1, which stimulates neovascularization in conjunction with the MM-derived VEGF. 55 
Prognostic value of angiogenesis in MM
The main steps assessing the prognostic value of bone marrow angiogenesis in MM are summarized in Table 2 . As bone marrow angiogenesis and LI% are closely associated with MM activity and mutually correlated, and because LI% is a prognostic factor, it may well be that a given disease state (MGUS, nonactive MM) is at risk of progression towards the subsequent larger-mass steady state (active MM) if the bone marrow shows angiogenesis. The risk would be the greater, the higher the LI% and the larger the microvessel area.
1 Microvessel area variations are therefore a useful guide to prognosis, just as LI% is. 1 The close correlation between bone marrow MVD and LI% in MM was confirmed by Rajkumar et al., 56 who also showed that patients with X50 microvessels/ Â 400 bone marrow field had a median survival of 2.6 years compared to the 5.1 years of those with o50 microvessels.
Angiogenesis is a prognostic factor for survival in MM. successful therapy in MM, whereas little or no reduction is apparent in nonresponders, so that these factors could be of prognostic relevance. 58 Accordingly, lowering of bone marrow MVD parallels response to high-dose chemotherapy with autologous stem cell transplantation, which corresponds to a significantly longer progression-free survival compared to persistent high MVD and nonresponse. 58 Moreover, bone marrow angiogenesis increases with MM progression from Durie & Salmon stage I to II-III. Its correlation with plasmocytosis and serum b2-microglobulin suggests that MM expansion needs bone marrow vascularization, which could thus be a prognostic factor. 59 A study of MVD in plasmocytoma and paired bone marrow biopsies was made by Kumar et al. 60 They showed 'high-grade' angiogenesis in 64% of plasmocytomas, whereas angiogenesis was absent in all bone marrows. Patients with high MVD were more likely to progress to MM and had a shorter progression-free survival compared to those with 'low-grade' angiogenesis. Bone marrow MVD at the time of initial diagnosis has a prognostic value for overall and progression-free survival in patients undergoing autologous transplantation as a frontline therapy. 61 
Evolution of a new treatment paradigm for MM
The emerging role of the bone marrow microenvironment throughout all malignant processes has provided the framework for development of a new MM paradigm targeting both the MM plasma cells and all microenvironment components. Novel therapeutic agents are currently under investigation (Table 3) . Among these, thalidomide exerts a remarkable antitumor effect early in the course 62 and in refractory and relapsed MM (see for a review Ribatti and Vacca 63 ). Although there are evidences that thalidomide therapy is associated with a decreased MVD, 64, 65 it is conceivable that besides its antiangiogenic effect multiple pathways may be involved in its activity. 63 Its structural analog, such as CC-5013, 66 CPS11 and CPS49, 67 have been synthesized to explore its potential molecular targets, as well as to identify new agents with improved therapeutic efficacy.
Concluding remarks
Overall studies indicate that MGUS and nonactive MM are the avascular phase of plasma cell tumors, and active MM the vascular phase, and MM plasma cells induce the angiogenic switch via an array of angiogenic cytokines. MM microenvironment is a source of other angiogenic cytokines and participates in induction of the full angiogenic response. Angiogenesis and secretion of proteinases by plasma cells may explain local and distant MM dissemination. Angiogenesis could be a prognostic marker for MM in much the same way as in solid tumors. A fascinating issue is whether MMEC are tumoral, as suggested by some indirect evidence. Table 2 Main steps proving the prognostic value of angiogenesis in MM Bone marrow MVD is correlated to plasma cell LI%. 1, 56 Bone marrow angiogenesis is a prognostic factor for survival. 57 Serum FGF-2, VEGF and HGF decrease significantly after successful therapy. 58 Bone marrow angiogenesis increases with MM progression and correlates with plasmocytosis and b2-microglobulin. 59 Bone marrow angiogenesis increases in solitary plasmocytoma, and predicts progression to MM. 60 Bone marrow MVD at the time of initial diagnosis is an important prognostic factor in patients undergoing high-dose therapy. 61 MVD, microvessel density. 
